Bone drug Zometa flops in breast cancer study

Dec 09, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- Doctors are reporting a stunning setback for a promising new approach for fighting breast cancer.

A large study found that the bone-building drug Zometa (zow-MAY-tuh) did not prevent the return of cancer or improve survival in women with early or mid-stage disease.

Zometa did seem to help women at least five years past or over 60. The drug's maker, Novartis AG, is considering further tests in those women. Studies also are testing similar drugs, bisphosphonates like Fosamax and Boniva, to see if they help prevent .

Zometa is currently used to treat cancer that has already spread to the bone. The new study will not change that or affect the use of other similar drugs for .

Explore further: New family of small RNAs boosts cell proliferation in cancer

0 shares

Related Stories

Novel cancer drug has potential, study reports

Nov 12, 2010

(PhysOrg.com) -- Monthly injections of the drug in breast cancer patients whose disease had spread to the bone helped reduce pain and prevent complications with less toxicity than current treatments.

FDA warns of fractures with osteoporosis drugs

Oct 13, 2010

(AP) -- Government health officials warned doctors and patients Wednesday about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs.

Breast cancer study halted

Jun 20, 2007

The U.S. National Cancer Institute halted a $100 million study of drugs designed to prevent breast cancer in women at risk for the disease.

Recommended for you

Researchers confirm gene p73's role in tumor growth

14 hours ago

A team of researchers at National Cancer Centre Singapore (NCCS) and Singapore General Hospital (SGH) has determined dual functionality gene p73, in both the promotion and suppression in tumour growth. The NCCS team also ...

Researchers define unique group of high-risk lymphoma patients

16 hours ago

The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.